Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of subcutaneous CT-P13 in moderately to severely active rheumatoid arthritis
2026-526538-15-00Phase 3Authorised
- Sponsor
- Celltrion
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Remsima + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: ACR50 response at Week 12. Planned start Oct 2026; status: authorised.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2026-526538-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526538-15-00.